Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study

Digestive and Liver Disease

Volumn 46, Issue 9, 2014, Pages 833-837

  Gragnani, Laura ^a   Fabbrizzi, Alessio ^a   Triboli, Elisa ^a   Urraro, Teresa ^a   Boldrini, Barbara ^a   Fognani, Elisa ^a   Piluso, Alessia ^a   Caini, Patrizio ^a   Ranieri, Jessica ^a   Monti, Monica ^a   Laffi, Giacomo ^a   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiviral therapy; Direct acting antiviral; Hepatitis C virus; Mixed cryoglobulinaemia

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; ERYTHROPOIETIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ADVANCED LIVER DISEASE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; LIVER DISEASE; MALE; NEUTROPENIA; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TRIPLE ANTIVIRAL THERAPY; VIREMIA; AGED; ARTHRALGIA; NEPHRITIS; PERIPHERAL NEUROPATHY; PURPURA; RAYNAUD PHENOMENON; SJOEGREN SYNDROME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS REPLICATION; WEAKNESS; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG COMBINATION; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROLINE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84906309287     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.05.017     Document Type: Article

References (29)

1. Ferri C., Sebastiani M., Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Seminars in Arthritis and Rheumatism 2004, 33:355-374.
2. La Civita L., Zignego A.L., Monti M., et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis and Rheumatism 1995, 38:1859-1860.
3. Zignego A.L., Gragnani L., Giannini C., et al. The hepatitis C virus infection as a systemic disease. Internal and Emergency Medicine 2012, 7:S201-S208.
4. Craxi A., Laffi G., Hepatitis Zignego A.L. C virus (HCV) infection: a systemic disease. Molecular Aspects of Medicine 2008, 29:85-95.
5. Meltzer M., Franklin E.C., Elias K., et al. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. American Journal of Medicine 1966, 40:837-856.
6. De Vita S., Soldano F., Isola M., et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases 2011, 70:1183-1190.
7. Quartuccio L., Isola M., Corazza L., et al. Performance of the preliminary classification criteria for cryoglobulinemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinemic vasculitis. Clinical and Experimental Rheumatology 2012, 30:48-52.
8. Cacoub P., Lidove O., Maisonobe T., et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis and Rheumatism 2002, 46:3317-3326.
9. Pietrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews 2011, 10:444-454.
10. Zignego A.L., Ferri C., Pileri S.A., et al. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and Liver Disease 2007, 39:2-17.
11. Saadoun D., Resche Rigon M., Thibault V., et al. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 2014, 73:831-837.
12. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
13. Stasi C., Triboli E., Arena U., et al. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. Journal of Translational Medicine 2014, 12:21.
14. Gaiani S., Gramantieri L., Venturoli N., et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. Journal of Hepatology 1997, 27:979-985.
15. Petrarca A., Rigacci L., Caini P., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010, 116:335-342.
16. Piluso A., Giannini C., Fognani E., et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. Journal of Viral Hepatitis 2013, 20:e107-e114.
17. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
18. Ronnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Current Opinion in Rheumatology 2013, 25:248-253.
19. Giannelli F., Moscarella S., Giannini C., et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003, 102:1196-1201.
20. Zignego A.L., Ferri C., Giannelli F., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Annals of Internal Medicine 2002, 137:571-580.
21. Hezode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Journal of Hepatology 2013, 59:434-441.
22. Chou R., Hartung D., Rahman B., et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Annals of Internal Medicine 2013, 158:114-123.
23. Ferri C., Monti M., La Civita L., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993, 82:3701-3704.
24. Zignego A.L., Giannini C., Gragnani L.H.C.V. HCV and lymphoproliferation. Clinical and Developmental Immunology 2012, 980942.
25. Giannini C., Petrarca A., Monti M., et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 2008, 111:2943-2945.
26. Saadoun D., Resche Rigon M., Sene D., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010, 116:326-334.
27. Dammacco F., Tucci F.A., Lauletta G., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010, 116:343-353.
28. Antonelli A., Fallahi P., Ferrari S.M., et al. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clinical Rheumatology 2013, 32:1147-1154.
29. Antonelli A., Fallahi P., Ferrari S.M., et al. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. International Journal of Immunopathology and Pharmacology 2013, 26:49-57.